康乃德生物 CNTB 深 滬
已收盤 11-14 16:00:00 美东时间
2.12
+0.440
+26.19%
華盛通- 最 高2.17
- 今 開1.61
- 成交量 104.20万股
- 最 低 1.59
- 昨 收 1.68
- 總市值 1.18亿
- 52周最高 2.86
- 市盈率 靜 --
- 換手率 1.87%
- 52周最低 0.51
- 委 比 -27.36%
- 總股本 5572.17万
- 歷史最高 29.274
- 量 比 7.75
- 振 幅 34.52%
- 歷史最低 0.51
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多中概股周涨跌榜 | 百济神州周累涨超15%创年内新高！公司营收同比大增；获小摩唱多，小鹏汽车周涨逾11%
百济神州周累涨超15%创年内新高！公司营收同比大增；获小摩唱多，小鹏汽车周涨逾11%>>
11-15 17:00
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
BTIG Reiterates Buy on Connect Biopharma Hldgs, Maintains $10 Price Target
BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $10 price target.
11-13 17:55
Connect Biopharma Hldgs Q3 EPS $(0.31) Misses $(0.27) Estimate, Sales $16.000K Down From $1.219M YoY
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.27) by 14.81 percent. This is a 34.78 percent decrease over losses of $(0.23) per
11-12 22:07
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Connect Biopharma reports progressing Phase 2 Seabreeze STAT studies for asthma and COPD exacerbations, with topline data expected in 2026. The company's licensee, Simcere, submitted a New Drug Application for rademikibart for atopic dermatitis, accepted by China's NMPA. Connect terminated its ADR program and listed ordinary shares directly on Nasdaq. Positive data from ERS 2025 highlighted rademikibart's potential efficacy across type 2 inflamma...
11-12 14:00
美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
BTIG Initiates Coverage On Connect Biopharma Hldgs with Buy Rating, Announces Price Target of $10
BTIG analyst Julian Harrison initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy rating and announces Price Target of $10.
10-31 18:16
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
Rademikibart, an investigational anti-IL-4Rα antibody, showed rapid and significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers. It reduced annualized asthma exacerbations by 63%-69% in subgroups with high biomarkers. The Phase 2b trial results support ongoing Seabreeze STAT studies for asthma and COPD, with topline data expected in H1 2026.
09-29 13:00
Connect Biopharma Executives Increase Share Holdings
Connect Biopharma Holdings ( ($CNTB) ) has issued an announcement. Between Sept...
09-16 21:26
中概股周涨跌榜 | Gamehaus Holdings涨66.7%；房多多涨64.8%；Next Technology跌63.5%，霸王茶姬跌18.3%
Gamehaus Holdings涨66.7%；房多多涨64.8%；Mercurity Fintech涨41.5%
08-30 17:08
